Patents by Inventor Ugur Sahin

Ugur Sahin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12273505
    Abstract: According to an example embodiment, a stereoscopic near-eye display (NED) assembly for a NED device including a pair of NED assemblies is provided, where an input image is subjected to a preprocessing procedure that applies image-area-position dependent preprocessing before providing it for viewing through a lens assembly that comprises a diffractive optical element (DOE) arranged to provide a phase delay that is different through a plurality of positions of its aperture. According to other example embodiments, an apparatus and a method for deriving the preprocessing procedure and the DOE are provided.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: April 8, 2025
    Assignee: TAMPERE UNIVERSITY FOUNDATION SR
    Inventors: Erdem Sahin, Ugur Akpinar, Atanas Gotchev, Rajesh Menon
  • Patent number: 12270813
    Abstract: The present invention relates to methods for predicting whether peptides or polypeptides comprising disease specific amino acid modifications, in particular tumor-associated neo-antigens, comprise epitopes, in particular tumor-associated neo-epitopes, which are useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: April 8, 2025
    Assignee: BioNTech SE
    Inventor: Ugur Sahin
  • Publication number: 20250092469
    Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
    Type: Application
    Filed: December 6, 2024
    Publication date: March 20, 2025
    Inventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
  • Patent number: 12208136
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: January 28, 2025
    Assignee: BioNTech SE
    Inventors: Alexander Muik, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin, Kayvon Modjarrad
  • Publication number: 20250025505
    Abstract: The present disclosure relates to chimeric antigen receptor (CAR) expressing immune effector cells showing highly specific and sensitive recognition of CLDN6 expressing cancer cells as well as a high potential for treating cancer in humans.
    Type: Application
    Filed: December 8, 2022
    Publication date: January 23, 2025
    Inventors: Ugur SAHIN, Petra OEHM, Benjamin RENGSTL, Katharina REINHARD, Liane Monika PREUSSNER, Özlem TÜRECI
  • Publication number: 20250027066
    Abstract: The invention provides agents and methods for treating bacterial infections using RNA. The RNA encoding peptidoglycan hydrolases. e.g., endolysins, is formulated and administered in a way that peptidoglycan hydrolase proteins. e.g., endolysin proteins, can be produced and secreted by cells of a subject to combat bacterial infections.
    Type: Application
    Filed: November 9, 2022
    Publication date: January 23, 2025
    Inventors: Ugur Sahin, Andreas Henning, Stephanie Erbar, Stefan Albrecht Schille, Anna Spier, Lorenzo Corsini, Zehra Visram
  • Publication number: 20250011797
    Abstract: The present invention relates to nucleic acid molecules containing poly(dA:dT) regions which are stabilized in E.coli, methods of propagating such nucleic acid molecules in E.coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly(dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.
    Type: Application
    Filed: June 7, 2024
    Publication date: January 9, 2025
    Inventors: Florian Eberle, Ugur Sahin, Andreas Kuhn, Britta Vallazza, Mustafa Diken
  • Publication number: 20250009780
    Abstract: The present invention generally relates to binding agents that are at least bispecific for the binding to CD3 and CLDN6, i.e., they are capable of binding to at least CD3 and CLDN6. Specifically, the present invention relates to RNA encoding these binding agents which may be used in the treatment or prevention of cancer in a subject.
    Type: Application
    Filed: July 13, 2022
    Publication date: January 9, 2025
    Inventors: Ugur SAHIN, Christiane STADLER, Claudia LINDEMANN, Ursula ELLINGHAUS, Hayat BÄHR-MAHMUD, Leyla FISCHER, Anuhar CHATURVEDI, Gábor BOROS, Jonas REINHOLZ, Sergey BESSONOV, Katalin KARIKÓ
  • Patent number: 12188097
    Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
    Type: Grant
    Filed: June 6, 2023
    Date of Patent: January 7, 2025
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
  • Patent number: 12186275
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: January 7, 2025
    Assignee: BioNTach Ceil & Gene Therapies GmbH and TRON—Translationaie Onkologie an der Universitaismedizin der Johannes Gutenberg-univer
    Inventors: Ugur Sahin, Katharina Reinhard, Petra Simon, Karolina Anna Mroz, Kathleen Hobohm
  • Patent number: 12186387
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: January 7, 2025
    Assignee: BioNTech SE
    Inventors: Alexander Muik, Asaf Poran, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin
  • Publication number: 20250002600
    Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.
    Type: Application
    Filed: October 5, 2022
    Publication date: January 2, 2025
    Inventors: Alexander MUIK, Kristina SCHÖDEL, Nora PENCHEVA, Maria N. JURE-KUNKEL, Ugur SAHIN, Sina FELLERMEIER-KOPF, Patricia GARRIDO CASTRO, Jordan BLUM, Friederike GIESEKE, Esther C. W. BREIJ, Lars GUELEN, Joost NEIJSSEN, Karsten BECKMANN, Claudia PAULMANN, Bart-Jan DE KREUK, Richard G. HIBBERT, Janine SCHUURMAN, Aran LABRIJN, Ivan KUZMANOV
  • Publication number: 20240415946
    Abstract: This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
    Type: Application
    Filed: October 10, 2022
    Publication date: December 19, 2024
    Inventors: Ugur SAHIN, David WEBER, Carina WALTER, Diana BAREA ROLDÁN, Ruprecht KUNER, Melanie HEIN, Martin SUCHAN,, Vetena KISSLER, Lena Mareen KRANZ
  • Publication number: 20240415828
    Abstract: The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.
    Type: Application
    Filed: November 9, 2022
    Publication date: December 19, 2024
    Inventors: Ugur SAHIN, Hariz Iskandar Bin HASSAN, Stefan STROBL, Roman RÖSEMANN
  • Patent number: 12168051
    Abstract: The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.
    Type: Grant
    Filed: September 12, 2022
    Date of Patent: December 17, 2024
    Assignees: BIONTECH SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventors: Mahjoub Bihi, Ugur Sahin, Mustafa Diken, Thorsten Klamp
  • Publication number: 20240409653
    Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.
    Type: Application
    Filed: October 5, 2022
    Publication date: December 12, 2024
    Inventors: Alexander MUIK, Kristina NÜRMBERGER, Nora PENCHEVA, Maria N. JURE-KUNKEL, Ugur SAHIN
  • Publication number: 20240400703
    Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: May 10, 2024
    Publication date: December 5, 2024
    Inventors: Kristel Kemper, Maarten van der Kroef, Dennis Verzijl, Andrea Gorlani, Pauline Linda de Goeje, Lars Guelen, David Satijn, Esther C. W. Breij, Ugur Sahin, Sina Fellermeier-Kopf, Maren Köhne
  • Publication number: 20240390524
    Abstract: Disclosed herein are RNA polynucleotides comprising a 5? Cap, a 5? UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.
    Type: Application
    Filed: April 5, 2024
    Publication date: November 28, 2024
    Inventors: Ugur Sahin, Gábor Boros, Azita Josefine Mahiny, Jonas Reinholz, Katalin Karikó
  • Patent number: 12153041
    Abstract: The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: November 26, 2024
    Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SE
    Inventors: Mathias Vormehr, Ugur Sahin, Barbara Schrörs, Martin Löwer, Sebastian Boegel
  • Patent number: 12150947
    Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: November 26, 2024
    Assignees: BioNTech SE, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Stephanie Erbar, Kerstin Walzer, Anne Schlegel, Sebastian Hörner, Jorge Herrero Moreno, Thorsten Klamp, Sebastian Kreiter, Mustafa Diken, Phillip Heller